260 related articles for article (PubMed ID: 23753531)
1. A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin.
Liu W; Zi M; Tsui H; Chowdhury SK; Zeef L; Meng QJ; Travis M; Prehar S; Berry A; Hanley NA; Neyses L; Xiao RP; Oceandy D; Ke Y; Solaro RJ; Cartwright EJ; Lei M; Wang X
Circ Heart Fail; 2013 Jul; 6(4):833-44. PubMed ID: 23753531
[TBL] [Abstract][Full Text] [Related]
2. Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart.
Liu W; Zi M; Naumann R; Ulm S; Jin J; Taglieri DM; Prehar S; Gui J; Tsui H; Xiao RP; Neyses L; Solaro RJ; Ke Y; Cartwright EJ; Lei M; Wang X
Circulation; 2011 Dec; 124(24):2702-15. PubMed ID: 22082674
[TBL] [Abstract][Full Text] [Related]
3. A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
Grund A; Szaroszyk M; Döppner JK; Malek Mohammadi M; Kattih B; Korf-Klingebiel M; Gigina A; Scherr M; Kensah G; Jara-Avaca M; Gruh I; Martin U; Wollert KC; Gohla A; Katus HA; Müller OJ; Bauersachs J; Heineke J
Cardiovasc Res; 2019 Jan; 115(1):71-82. PubMed ID: 29931050
[TBL] [Abstract][Full Text] [Related]
4. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
[TBL] [Abstract][Full Text] [Related]
5. Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7.
Li X; Chu G; Zhu F; Zheng Z; Wang X; Zhang G; Wang F
Exp Cell Res; 2020 Jan; 386(1):111716. PubMed ID: 31734152
[TBL] [Abstract][Full Text] [Related]
6. Zerumbone prevents pressure overload-induced left ventricular systolic dysfunction by inhibiting cardiac hypertrophy and fibrosis.
Sari N; Katanasaka Y; Sugiyama Y; Sunagawa Y; Miyazaki Y; Funamoto M; Shimizu S; Shimizu K; Murakami A; Mori K; Wada H; Hasegawa K; Morimoto T
Phytomedicine; 2021 Nov; 92():153744. PubMed ID: 34563985
[TBL] [Abstract][Full Text] [Related]
7. Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice.
Weng LQ; Zhang WB; Ye Y; Yin PP; Yuan J; Wang XX; Kang L; Jiang SS; You JY; Wu J; Gong H; Ge JB; Zou YZ
Acta Pharmacol Sin; 2014 Aug; 35(8):1005-14. PubMed ID: 24998254
[TBL] [Abstract][Full Text] [Related]
8. FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning.
Vessey DA; Li L; Imhof I; Honbo N; Karliner JS
Med Sci Monit Basic Res; 2013 Apr; 19():126-32. PubMed ID: 23567658
[TBL] [Abstract][Full Text] [Related]
9. CTGF knockout does not affect cardiac hypertrophy and fibrosis formation upon chronic pressure overload.
Fontes MS; Kessler EL; van Stuijvenberg L; Brans MA; Falke LL; Kok B; Leask A; van Rijen HV; Vos MA; Goldschmeding R; van Veen TA
J Mol Cell Cardiol; 2015 Nov; 88():82-90. PubMed ID: 26410398
[TBL] [Abstract][Full Text] [Related]
10. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.
Liu Q; Chen Y; Auger-Messier M; Molkentin JD
Circ Res; 2012 Apr; 110(8):1077-86. PubMed ID: 22403241
[TBL] [Abstract][Full Text] [Related]
11. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
[TBL] [Abstract][Full Text] [Related]
12. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy.
Moens AL; Takimoto E; Tocchetti CG; Chakir K; Bedja D; Cormaci G; Ketner EA; Majmudar M; Gabrielson K; Halushka MK; Mitchell JB; Biswal S; Channon KM; Wolin MS; Alp NJ; Paolocci N; Champion HC; Kass DA
Circulation; 2008 May; 117(20):2626-36. PubMed ID: 18474817
[TBL] [Abstract][Full Text] [Related]
13. Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload.
Calamaras TD; Baumgartner RA; Aronovitz MJ; McLaughlin AL; Tam K; Richards DA; Cooper CW; Li N; Baur WE; Qiao X; Wang GR; Davis RJ; Kapur NK; Karas RH; Blanton RM
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H145-H159. PubMed ID: 30362822
[TBL] [Abstract][Full Text] [Related]
14. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
[TBL] [Abstract][Full Text] [Related]
15. Peroxiredoxin-1 ameliorates pressure overload-induced cardiac hypertrophy and fibrosis.
Tang C; Yin G; Huang C; Wang H; Gao J; Luo J; Zhang Z; Wang J; Hong J; Chai X
Biomed Pharmacother; 2020 Sep; 129():110357. PubMed ID: 32531679
[TBL] [Abstract][Full Text] [Related]
16. 6-Gingerol protects against cardiac remodeling by inhibiting the p38 mitogen-activated protein kinase pathway.
Ma SQ; Guo Z; Liu FY; Hasan SG; Yang D; Tang N; An P; Wang MY; Wu HM; Yang Z; Fan D; Tang QZ
Acta Pharmacol Sin; 2021 Oct; 42(10):1575-1586. PubMed ID: 33462378
[TBL] [Abstract][Full Text] [Related]
17. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
18. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).
Taylor PA; Ehrhardt MJ; Lees CJ; Tolar J; Weigel BJ; Panoskaltsis-Mortari A; Serody JS; Brinkmann V; Blazar BR
Blood; 2007 Nov; 110(9):3480-8. PubMed ID: 17606761
[TBL] [Abstract][Full Text] [Related]
19. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
Takimoto E; Champion HC; Li M; Belardi D; Ren S; Rodriguez ER; Bedja D; Gabrielson KL; Wang Y; Kass DA
Nat Med; 2005 Feb; 11(2):214-22. PubMed ID: 15665834
[TBL] [Abstract][Full Text] [Related]
20. Belumosudil, ROCK2-specific inhibitor, alleviates cardiac fibrosis by inhibiting cardiac fibroblasts activation.
Liu Q; Li HY; Wang SJ; Huang SQ; Yue Y; Maihemuti A; Zhang Y; Huang L; Luo L; Feng KN; Wu ZK
Am J Physiol Heart Circ Physiol; 2022 Jul; 323(1):H235-H247. PubMed ID: 35657612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
